| Titolo |
Pubblicato in |
Anno |
| Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma |
JOURNAL OF CLINICAL ONCOLOGY |
2017 |
| Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? |
EXPERT REVIEW OF HEMATOLOGY |
2017 |
| PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS |
22nd Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2017 |
| Rituximab and autologous stem-cell transplantation for high-risk diffuse large B-cell lymphoma - Authors' reply |
THE LANCET ONCOLOGY |
2017 |
| EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP |
HAEMATOLOGICA |
2017 |
| Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper |
EUROPEAN JOURNAL OF HAEMATOLOGY |
2016 |
| The 68Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma) |
PHYSICA MEDICA |
2016 |
| Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up |
ANNALS OF ONCOLOGY |
2016 |
| Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: Interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study |
HEMATOLOGICAL ONCOLOGY |
2016 |
| CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE CENTER ANALYSIS OF THE RISK FACTORS AND THE IMPACT OF CNS PROPHYLAXIS IN THE RITUXIMAB ERA |
21st Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2016 |
| Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) |
THE ONCOLOGIST |
2015 |
| Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma |
BLOOD |
2015 |
| Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: A prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL) |
LEUKEMIA & LYMPHOMA |
2015 |
| PET scanner clinical trial qualification for worldwide onco-hematological studies |
LEUKEMIA & LYMPHOMALEUKEMIA & LYMPHOMA |
2015 |
| HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY |
20th Congress of European-Hematology-AssociationHAEMATOLOGICA |
2015 |
| THE IELSG-32 TRIAL: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE AND HIGH-DOSE CYTARABINE WITH OR WITHOUT THIOTEPA, AND WITH OR WITHOUT RITUXIMAB, FOLLOWED BY BRAIN IRRADIATION VS HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AUTOLOGOUS STEM CELLS TRANSPLANTATION FOR IMMUNOCOMPETENT PATIENTS WITH NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA |
45th Congress of the Italian-Society-of-HematologyHAEMATOLOGICA |
2015 |
